Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21235507 | 0.89 | KMT2A (0.40) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12390736 | 0.78 | KMT2A (0.40) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL14238168 | 0.77 | LMNA (0.43) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL14239003 | 0.74 | KMT2A (0.37) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12207806 | 0.74 | KMT2A (0.40) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL18916054 | 0.73 | KMT2A (0.36) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL22007496 | 0.73 | KMT2A (0.39) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12390738 | 0.70 | TYMP (0.34) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL18916053 | 0.70 | KMT2A (0.38) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL6131653 | 0.69 | KMT2A (0.37) | KMT2ALMNATHRBCYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | KMT2A 2870/4885LMNA 2646/4885THRB 428/4885 |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | KMT2A 2870/4885LMNA 2646/4885THRB 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.